Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease 2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received theophylline and the other required a temporary pacemaker. Fortunately, the patients' heart rate and rhythm returned to normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir infusion may decrease the risk of adverse cardiovascular side effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742862 | PMC |
| http://dx.doi.org/10.18502/jthc.v16i2.7390 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.
Int J Crit Illn Inj Sci
December 2024
Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Background: Remdesivir is commonly used for inpatient treatment of coronavirus disease of 2019 (COVID-19) and may be associated with bradycardia. The objective is to investigate the incidence of bradycardia in patients with COVID-19 receiving remdesivir and evaluate potential risk factors associated with bradycardia.
Methods: This single-center, retrospective, cohort study evaluated the incidence of bradycardia during and up to 48 h after remdesivir administration in adults admitted to the medical center for treatment of COVID-19.
An updated meta-analysis of pooled incidence of remdesivir-associated bradycardia.
J Med Virol
April 2024
Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.
Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.
BMJ Open
May 2023
Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, Nevada, USA
Introduction: Remdesivir is an antiviral medication that is used in the treatment of severe COVID-19. Research has highlighted the potential cardiac side effects of remdesivir, including the occurrence of remdesivir-associated bradycardia (RAB), but these findings have not been consistent. In addition, very little is known about the clinical implications and outcomes of RAB.
View Article and Find Full Text PDFIncidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study.
Front Pharmacol
February 2023
Division of Infectious Diseases, Department of Medicine, The Warren Alpert Medical School, Brown University and Rhode Island Hospital, Providence, RI, United States.
Remdesivir is widely used for the management of COVID-19 and several studies have reported bradycardia as a potential side effect associated with this agent. The aim of the present study was to evaluate the incidence rate, severity, and potential risk factors of remdesivir-associated bradycardia. We performed a retrospective cohort study among hospitalized adult patients with COVID-19 who were treated with remdesivir from March 2020 to October 2021.
View Article and Find Full Text PDFRemdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.
Front Pharmacol
January 2023
Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim of the present study is investigating the incidence of bradycardia in COVID-19 patients treated with Remdesivir. This prospective longitudinal study was conducted in a tertiary center on COVID-19 patients for Remdesivir therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!